Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SNDX – Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.
SNDX
$20.34
Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,767,847,808.00
EPSttm : -3.6
finviz dynamic chart for SNDX
Syndax Pharmaceuticals, Inc.
$20.34
0.59%
$0.12

Float Short %

27.08

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

0.16

EPS Last/This Y

0.67

EPS This/Next Y

1.31

Price

20.34

Target Price

39.31

Analyst Recom

1.07

Performance Q

24.02

Relative Volume

0.55

Beta

0.46

Ticker: SNDX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-08SNDX19.950.311.5236866
2025-12-09SNDX19.510.320.1337243
2025-12-10SNDX20.620.320.0237345
2025-12-11SNDX20.410.320.2537443
2025-12-12SNDX20.360.320.1637459
2025-12-15SNDX20.860.330.0136594
2025-12-16SNDX20.740.330.0037163
2025-12-17SNDX20.380.350.0635732
2025-12-18SNDX20.230.340.1635745
2025-12-19SNDX20.770.350.0935758
2025-12-22SNDX21.480.370.0926464
2025-12-23SNDX21.70.360.0626842
2025-12-26SNDX21.280.360.6626927
2025-12-29SNDX21.070.360.0126938
2025-12-30SNDX20.730.360.0826923
2025-12-31SNDX21.020.350.0127219
2026-01-02SNDX21.30.350.9027433
2026-01-05SNDX20.240.370.0227919
2026-01-06SNDX20.350.350.0229383
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-08SNDX19.9847.0- -3.05
2025-12-09SNDX19.5147.0216.5-3.05
2025-12-10SNDX20.6547.0208.9-3.05
2025-12-11SNDX20.3947.0215.5-3.05
2025-12-12SNDX20.3547.0214.6-3.05
2025-12-15SNDX20.8847.0212.0-3.05
2025-12-16SNDX20.8847.0215.0-3.05
2025-12-17SNDX20.3847.0215.8-3.05
2025-12-18SNDX20.2347.0215.0-3.05
2025-12-19SNDX20.7747.0211.9-3.05
2025-12-22SNDX21.4447.0211.6-3.05
2025-12-23SNDX21.8347.0213.6-3.05
2025-12-26SNDX21.3147.0215.5-3.05
2025-12-29SNDX21.0747.0215.3-3.05
2025-12-30SNDX20.7247.0215.8-3.05
2025-12-31SNDX21.0247.0213.1-3.05
2026-01-02SNDX21.3047.0213.0-3.05
2026-01-05SNDX20.2247.0218.9-3.05
2026-01-06SNDX20.3447.0213.8-3.05
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-08SNDX-7.83-3.4730.40
2025-12-09SNDX-7.83-3.4730.40
2025-12-10SNDX-7.83-3.4729.93
2025-12-11SNDX-7.83-3.4729.93
2025-12-12SNDX-7.83-3.4729.93
2025-12-15SNDX-7.83-3.4729.92
2025-12-16SNDX-7.88-3.4729.92
2025-12-17SNDX-7.88-3.4729.92
2025-12-18SNDX-7.88-3.4729.92
2025-12-19SNDX-7.88-3.4729.92
2025-12-22SNDX-7.88-3.4729.92
2025-12-23SNDX-7.88-3.4729.92
2025-12-26SNDX-7.88-3.4727.08
2025-12-29SNDX-7.88-3.4727.08
2025-12-30SNDX-7.88-3.4727.08
2025-12-31SNDX-7.88-3.4727.08
2026-01-02SNDX-7.88-3.4727.08
2026-01-05SNDX-7.88-3.5427.08
2026-01-06SNDX-7.88-3.5427.08
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.7

Avg. EPS Est. Current Quarter

-0.58

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-7.88

Institutional Transactions

-3.54

Beta

0.46

Average Sales Estimate Current Quarter

64

Average Sales Estimate Next Quarter

70

Fair Value

Quality Score

41

Growth Score

40

Sentiment Score

54

Actual DrawDown %

31.9

Max Drawdown 5-Year %

-69.9

Target Price

39.31

P/E

Forward P/E

PEG

P/S

15.85

P/B

15.31

P/Free Cash Flow

EPS

-3.62

Average EPS Est. Cur. Y​

-3.05

EPS Next Y. (Est.)

-1.74

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-279.31

Relative Volume

0.55

Return on Equity vs Sector %

-297

Return on Equity vs Industry %

-281.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

213.8
Syndax Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading